COVID 19 is the #63 most commonly reported adverse reaction for NYSTATIN, manufactured by Padagis US LLC. There are 363 FDA adverse event reports linking NYSTATIN to COVID 19. This represents approximately 0.6% of all 59,130 adverse event reports for this drug.
NYSTATIN has an overall safety score of 82 out of 100. Patients taking NYSTATIN who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
COVID 19363 of 59,130 reports
COVID 19 is a less commonly reported adverse event for NYSTATIN, but still significant enough to appear in the safety profile.
Other Side Effects of NYSTATIN
In addition to covid 19, the following adverse reactions have been reported for NYSTATIN:
COVID 19 has been reported as an adverse event in 363 FDA reports for NYSTATIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is COVID 19 with NYSTATIN?
COVID 19 accounts for approximately 0.6% of all adverse event reports for NYSTATIN, making it a notable side effect.
What should I do if I experience COVID 19 while taking NYSTATIN?
If you experience covid 19 while taking NYSTATIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.